Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.

Antiviral research - 1 Nov 2024

Lo Chieh-Wen, Kariv Omri, Hao Chenzhou, Gammeltoft Karen Anbro, Bukh Jens, Gottwein Judith, Westberg Michael, Lin Michael Z, Einav Shirit

Abstract excerpt

There is an ongoing need to expand the anti-SARS-CoV-2 armamentarium to include agents capable of suppressing replication of drug-resistant mutants emerging during monotherapy with approved direct-acting antivirals. Using a subgenomic SARS-CoV-2 replicon system, we studied the RNA replication capacity of nirmatrelvir (NTV)-resistant mutants and their susceptibility to next-generation Mpro inhibitors, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Drug Treatment
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams

Share to Leucine

Share to Nitriles

Share to Proline

Share to Replicon

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 39424074
DOI: 10.1016/j.antiviral.2024.106022
PMCID: PMC11578872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.PMID 39424074Read ↗

Replication Capacity and Susceptibility of Nirmatrelvir-Resistant Mutants to Next-Generation Mpro Inhibitors in a SARS-CoV-2 Replicon SystemSemantic proximity Read ↗

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals.Semantic proximity Read ↗

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvirSemantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read ↗

Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape StrategiesSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of NirmatrelvirSemantic proximity Read ↗

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read ↗

SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug ResistanceSemantic proximity Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.